Table 2 Development of the two-step risk stratification model
Characteristics | Univariate Cox analysis | Multivariate Cox analysis | ||||
|---|---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | β value | Points | |
(A) Analysis of risk factors for distant failure in the non-LRRT cohort. Six variables selected through LASSO regression were included in the multivariate analysis. The β coefficients of these variables, representing their relative contributions to the model, were rounded to the nearest integer and assigned as corresponding scores. | ||||||
No. of metastatic organs (>1 vs 1) | 2.492 (1.558–3.989) | <0.001 | 1.762 (1.056–2.939) | 0.030 | 0.566 | 1 |
No of metastatic lesions (>3 vs ≤3) | 3.368 (1.960–5.787) | <0.001 | 0.24 | |||
Liver metastasis (yes vs no) | 1.803 (1.153–2.280) | 0.010 | 0.57 | |||
Baseline LDH level, U/L (≥500 vs <500) | 3.371 (2.061–5.514) | <0.001 | 2.763 (1.561–4.892) | <0.001 | 1.016 | 1 |
EBV DNA level after first-line immunochemotherapy (detectable vs undetectable) | 4.293 (2.712–6.798) | <0.001 | 3.198 (1.963–5.209) | <0.001 | 1.163 | 1 |
Response evaluation after first-line immunochemotherapy (SD/PD vs CR/PR) | 5.020 (3.038–8.294) | <0.001 | 4.675 (2.715–8.051) | <0.001 | 1.542 | 2 |
(B) Analysis of risk factors for locoregional failure in the non-LRRT cohort. Two variables selected through LASSO regression were included in the multivariate analysis. The β coefficients of these variables, representing their relative contributions to the model, were rounded to the nearest integer and assigned as corresponding scores. | ||||||
EBV DNA level after one cycle (detectable vs undetectable) | 3.447 (1.850–6.422) | <0.001 | 2.416 (1.240–4.706) | 0.010 | 0.882 | 1 |
The initial assessment of locoregional response (DpR ≤70% vs >70%) | 3.481 (1.941–6.241) | <0.001 | 2.517 (1.349–4.697) | 0.004 | 0.923 | 1 |
